Issue 2/2018
Content (23 Articles)
Positioning of proteasome inhibitors in therapy of solid malignancies
Margot S. F. Roeten, Jacqueline Cloos, Gerrit Jansen
B7-H3 in tumors: friend or foe for tumor immunity?
Gen Li, Yanchun Quan, Fengyuan Che, Lijuan Wang
Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations
Xiaojun Liu, Yingjun Jiang, Billie Nowak, Bethany Qiang, Nancy Cheng, Yuling Chen, William Plunkett
Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study
Tadahiko Shien, Hiroyoshi Doihara, Nobuaki Sato, Keisei Anan, Kansei Komaki, Keisuke Miyauchi, Yasuhiro Yanagita, Tomomi Fujisawa, Shoshu Mitsuyama, Chizuko Kanbayashi, Mikihiro Kusama, Morihiko Kimura, Hiromitsu Jinno, Muneaki Sano, Tadashi Ikeda
Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine
Lee Cheng Phua, Shixu Goh, David Wai Meng Tai, Wei Qiang Leow, Syed Muhammad Fahmy Alkaff, Chung Yip Chan, Juinn Huar Kam, Tony Kiat Hon Lim, Eric Chun Yong Chan
A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin—integration of in vitro results, Phase I and Phase II data and model application for drug–drug interaction potential analysis
Nina Hanke, Michael Teifel, Daniel Moj, Jan-Georg Wojtyniak, Hannah Britz, Babette Aicher, Herbert Sindermann, Nicola Ammer, Thorsten Lehr
Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemia
Swantje Völler, Uwe Pichlmeier, Anke Zens, Georg Hempel
Influence of the ABCB1 polymorphisms on the response to Taxane-containing chemotherapy: a systematic review and meta-analysis
Qi Jiang, Meizhen Xu, Yina Liu, Yudi Chen, Jiarong Feng, Xuelin Wang, Shuang Liang, Dan Li, Xiaoqin Yang
Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma
Hitesh B. Mistry, David Orrell, Raluca Eftimie
Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study
Yuki Kataoka, Katsuya Hirano, Tomoko Narabayashi, Satoshi Hara, Daichi Fujimoto, Tae Tanaka, Noriyuki Ebi, Keisuke Tomii, Hiroshige Yoshioka
A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting
Ichidai Tanaka, Kenji Kawada, Masahiro Morise, Tetsunari Hase, Hiroaki Hayashi, Akihiko Sokai, Asuki Fukatsu, Masashi Kondo, Fumio Nomura, Yoshinori Hasegawa
Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients
L. K. Schoch, A. Asiama, M. Zahurak, S. Shanbhag, J. Hurtt, K. Sawyer, L. J. Swinnen, N. Wagner-Johnston, R. J. Jones, R. F. Ambinder, Douglas E. Gladstone
Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors
Emily Chan, E. Gabriela Chiorean, Peter J. O’Dwyer, Nashat Y. Gabrail, Thierry Alcindor, Diane Potvin, Richard Chao, Herbert Hurwitz
CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine
Xinna Zhou, Guoliang Qiao, Xiaoli Wang, Qingkun Song, Michael A. Morse, Amy Hobeika, William R. Gwin, Jun Ren, H. Kim Lyerly
Immunological hallmarks of cis-DDP-resistant Lewis lung carcinoma cells
Olexandr Fedorchuk, Yaroslav Susak, Mariia Rudyk, Nataliia Senchylo, Nataliia Khranovska, Oksana Skachkova, Larysa Skivka
A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study)
Shunsuke Kagawa, Atsushi Muraoka, Takeshi Kambara, Hiroshi Nakayama, Ryosuke Hamano, Norimitsu Tanaka, Kazuhiro Noma, Kohji Tanakaya, Hiroyuki Kishimoto, Kunitoshi Shigeyasu, Shinji Kuroda, Satoru Kikuchi, Kazuya Kuwada, Masahiko Nishizaki, Yasuhiro Shirakawa, Toshiyoshi Fujiwara
A pilot study of daunorubicin-augmented hyper-CVAD induction chemotherapy for adults with acute lymphoblastic leukemia
Sung-Yong Kim, Ji Hyun Park, So Young Yoon, Yo-Han Cho, Mark Hong Lee
Prediction of neutrophil reduction using plasma paclitaxel concentration after administration in patients with uterine, ovarian, or cervical cancers in an outpatient clinic
Motoaki Ishikawa, Michiyasu Kawai, Toshio Maeda, Yoshiyuki Kagawa
The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer
Grant R. Williams, Allison M. Deal, Shlomit Strulov Shachar, Christine M. Walko, Jai N. Patel, Bert O’Neil, Howard L. McLeod, Marc S. Weinberg, Seul Ki Choi, Hyman B. Muss, Hanna K. Sanoff
Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men
Richard Markus, Vincent Chow, Zhiying Pan, Vladimir Hanes
Correction to: Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)
Shang-Chiung Chen, Matts Kagedal, Yuying Gao, Bei Wang, Marie-Laurence Harle-Yge, Sandhya Girish, Jin Jin, Chunze Li
Correction to: Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study
Jan de Jong, Peter Hellemans, James Juhui Jiao, Yuhan Huang, Sofie Mesens, Juthamas Sukbuntherng, Daniele Ouellet